Drugs / GLPG0492
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01538420 | Jan → Mar 2012 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT01397370 | Jul → Dec 2011 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT01130818 | May → Aug 2010 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2010-05-20 | Lakefront Biotherapeutics NV | Regulatory Galapagos initiates clinical studies with GLPG0492, a candidate drug for cachexia lakefrontbio.com ↗
Galapagos NV (Euronext: GLPG) announced today that it has initiated a first-in-human trial for GLPG0492, its candidate drug for cachexia (loss of weight and muscle mass) and potentially other indications, such as Duchenne muscular dystrophy. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2010-05-20 | Lakefront Biotherapeutics NV | Galapagos initiates clinical studies with GLPG0492, a candidate drug for cachexia lakefrontbio.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLPG0492 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01538420 ↗ |
| Known as | DT-200 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2178100 ↗ |
| Known as | G 100192 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2178100 ↗ |
| Modality | Small molecule | “GLPG0492 is a selective androgen receptor modulator” NCT01538420 ↗ |
| Route | Oral | “single ascending (SAD) oral dose of GLPG0492” NCT01130818 ↗ |
| Target | AR | “Androgen Receptor modulator” CHEMBL2178100 ↗ |